A large number of in vivo studies have indicated that the binding of the first-generation tau tracers (THK family, [18F]AV1451, [11C]PBB3), in contrast to the binding of amyloid-β tracers, is associated with different cognitive measures in patients with prodromal or dementia-stage AD, in agreement with the available postmortem studies [40, 42, 44, 50, 59, 153, 166, 183, 184, 207, 208]. This evidence concerns the gene MAPT and dementia.